UK-based biotechnology company Critical Pharmaceuticals is to collaborate with the University of Nottingham for the development of a nano-enabled intranasal formulation of teriparatide.
Funding worth £545,000 has been provided by the Technology Strategy Board and the Engineering and Physical Sciences Research Council to support the project, designed to create a technology-enabled treatment of osteoporosis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Teriparatide is commonly used to treat osteoporosis but is currently administered through a daily injection.
The collaboration hopes to develop a nasal spray formulation of the drug, enabling patients to easily administer teriparatide themselves and enhance the drug’s overall efficacy.
Critical Pharmaceuticals hopes to use its CriticalSorb nanotechnology, a best in class absorption promoter that is currently being used alongside a nasal formulation of human growth hormone (CP024), currently in phase I clinical development.
Osteoporosis affects an estimated 75 million people across Europe, the US and Japan.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
